Clinical Trials
12 trialsNCT04086485 2026-05-22
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT05064514 2026-05-08
TRICAR
Queen Mary University of London
Phase NA Active not recruiting
NCT07087054 2026-04-30
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
NCT07165132 2026-04-13
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
Phase 1 Recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT05361668 2026-03-19
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Phase 2 Completed
NCT04907643 2026-02-20
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
Phase NA Recruiting
NCT04993261 2026-02-19
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT02826928 2026-01-21
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
CHU de Reims
Phase NA Completed
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT02628067 2025-09-22
KEYNOTE 158
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting